AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.